skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis

Original Research

(2014) Views  (712) Full article downloads

Authors: Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, et al

Published Date April 2010 Volume 2010:6 Pages 201 - 206
DOI: http://dx.doi.org/10.2147/TCRM.S10136

Jun Iwamoto1, Yoshihiro Sato2, Mitsuyoshi Uzawa3, Tsuyoshi Takeda1, Hideo Matsumoto1

1Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Neurology, Mitate Hospital, Fukuoka, Japan; 3Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, Japan

Abstract: A retrospective study was performed to evaluate the outcome of alendronate (ALN) treatment for seven years in postmenopausal Japanese women with osteoporosis. Forty-seven postmenopausal women with osteoporosis (mean age at baseline 65.7 years) treated with ALN for over seven years in our outpatient clinic were analyzed. Lumbar spine bone mineral density (BMD) was measured using dual energy X-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum alkaline phosphatase (ALP) were monitored during the seven-year treatment period. Urinary NTX and serum ALP levels decreased (-48.2% at three months and -15.7% at seven years, respectively) and lumbar spine BMD increased (+12.8% at seven years) compared with baseline values. No serious adverse events were observed, including osteonecrosis of jaw, atypical femoral diaphysis fractures, or atrial fibrillation. To our knowledge, this is the first report of the outcome of ALN treatment for seven years in Japanese patients with osteoporosis. ALN successfully suppressed bone turnover and increased lumbar spine BMD from the baseline value over the course of the seven-year treatment period without causing any severe adverse events.

Keywords: alendronate, osteoporosis, long-term treatment, bone mineral density, bone turnover






 

Other articles by Dr Jun Iwamoto

Rat model of nonalcoholic steatohepatitis created by methionine and choline deficiency: biochemical and histological analyses


Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures
Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
Return to play after conservative treatment in athletes with symptomatic lumbar disc herniation: a practice-based observational study


Readers of this article also read:

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
Current trends in the treatment of polycystic ovary syndrome with desire for children
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient  onsiderations and the role of lisdexamfetamine
Treatment of congestion in upper respiratory diseases
Alendronate improves QOL of postmenopausal women with osteoporosis
Duloxetine in the management of diabetic peripheral neuropathic pain
Erratum